Cyclic ADP-ribose (cADPR) is a potent and universal intracellular calcium mobilizer, recently shown to behave as a new hemopoietic cytokine stimulating the in vitro proliferation of both committed and uncommitted human hemopoietic progenitors (HP). Here, we investigated the effects of cADPR on engraftment of hemopoietic stem cells (HSC) into irradiated NOD/SCID mice. Two different protocols were used: i) a 24 h in vitro priming of cord blood-derived mononuclear cells (MNC) with micromolar cADPR, followed by their infusion into irradiated mice (both primary and secondary transplants); and ii) co-infusion of MNC with CD38-transfected, cADPR-generating, irradiated murine 3T3 fibroblasts. We demonstrated a dual effect of cADPR on human HP in vivo: i) enhanced proliferation of committed progenitors, responsible for improvement of short-term engraftment; ii) expansion of HSC, with increased long-term human engraftment into secondary recipients and a significantly higher expansion factor of CD34 + progenitors in mice co-infused with MNC and CD38 + 3T3 fibroblasts. These results hold promise for the possible therapeutic use of cADPR, and of cADPR-producing stroma, to achieve long-term expansion of human HSC, that is, those HP capable of self-renewal and responsible for repopulation of the bone marrow.
C yclic ADP-ribose (cADPR), a potent and universal calcium mobilizer from intracellular stores (1, 2) , is attracting growing interest in the area of calcium signaling and of cell regulation in general. Its interplay with NAADP + and inositol 1-, 4-, 5-trisphosphate (Ins P3) is emerging as an increasingly important way to modulate Ca 2+ -dependent processes and functions in a wide number of cells (1) (2) (3) (4) . Among other biological roles, cADPR has recently been shown to behave as a new hemopoietic cytokine. Micromolar concentrations of exogenously added cADPR, or nanomolar concentrations of this cyclic nucleotide generated via a paracrine mechanism by ADP-ribosyl cyclase positive feeder layers, stimulate the in vitro proliferation of human hemopoietic progenitors (HP), both committed (colony-forming cells, CFC) (5) and uncommitted (long-term culture initiating cells, LTC-IC) (6) . Enhanced HP proliferation is causally related to the Ca 2+ -mobilizing activity of cADPR and has been observed also in non-hemopoietic autocrine and paracrine cell models (7, 8) .
Extracellular cADPR can be produced in the bone marrow (BM) microenvironment due to the presence of the required catalytic and transporting activities: i) the ecto-ADP-ribosyl cyclases CD38 and BST-1, expressed on the more mature HP (9, 10) and on stromal cells (11) , respectively, and, ii) NAD + -releasing connexin 43 hemichannels (12) , present on stromal cell, that make NAD + available to the ectocellular catalytic site of either cyclase, thereby enabling cADPR production. The broad spectrum of hemopoietic target cells responsive to cADPR (which includes committed and early progenitors), the mechanism of action of this cyclic nucleotide [via intracellular calcium movements, one of the most ancient and universal intracellular signals (2-4)], and its paracrine production by the hemopoietic stroma suggest that cADPR may exert its effect also on the most immature HP, that is, the hemopoietic stem cells (HSC) capable of self-renewal and responsible for repopulation of the BM. How little we know about this tiny HP subpopulation (13) (14) (15) is exemplified by our current inability to identify the HSC responsible for engraftment during allogeneic or autologous transplantation or to expand them in vitro.
This study aimed to assess the effect of cADPR on the self-renewal and expansion of human HSC. In the absence of specific phenotypic markers enabling their detection/quantitation, human HSC were identified through their engraftment capacity into irradiated NOD/SCID mice (16) (17) (18) .
MATERIALS AND METHODS

Samples
Cord blood (CB) samples were obtained from umbilical and placental tissues scheduled for discard (5) . CB cells were collected in tubes containing heparin, and the light-density (LD) fraction (<1.077g/ml) was isolated by centrifugation of the blood on a Ficoll/Hypaque solution (Pharmacia, Piscataway, NJ).
Animals
Breeding pairs of NOD/LtSz-scid/scid (NOD/SCID) mice (kindly provided by T. Lapidot, Weizmann Institute, Rehovot, Israel) were expanded and maintained in the animal facility of the Advanced Center of Biotechnology (ACB, Genova, Italy) in microisolators, under defined sterile conditions. Mice were irradiated at 6-8 weeks of age with a sublethal dose of 320-400 cGy of a 60 Co source a few hours before being given an intravenous injection of different numbers of LD-human cord blood cells.
All assays to detect human engraftment were performed on individual animals. Baseline levels of all parameters were established in the BM and spleen of sublethally irradiated NOD-SCID mice not receiving transplants.
Flow cytometry
Cell suspensions from femurs and spleen were collected in 2% fetal calf serum (FCS) in Hank's solution buffered with HEPES, subjected to red cell lysis by treatment with ammonium chloride, washed once and then resuspended in phosphate buffered saline (PBS; Parc Tech., Varilhes, France). After blocking the Fc receptors by pretreatment of the cells with human serum and an anti-mouse IgG receptor antibody (Beckton Dickinson, San Jose, CA), aliquots were stained at 4°C with a combination of an anti-CD45 antibody directly labeled with fluorescein isothiocyanate (FITC) (Beckton Dickinson) and an anti-CD71-FITC (Beckton Dickinson), to measure the proportion of human cells. Human CD45 positivity was used to identify and gate for human cells. To assess the specificity of the use of huCD45 antigen expression to detect human cells in a murine background, spiking experiments using known quantities of mouse and human cells were performed. Aliquots of cells were further stained with an anti-CD34 antibody and an anti-CD33 antibody (Beckton Dickinson) labeled with phycoerythrin to identify the progenitor cell compartment and the myeloid lineage, respectively.
Functional in vitro assays for hemopoietic progenitors
The standard methylcellulose-based semisolid assay using recombinant human hemopoietic growth factors (IL3, 10 ng/ml; GM-CSF, 10 ng/ml; SCF, 10 ng/ml; and erythropoietin, 5 U/ml, all from Genzyme, Cambridge, MA) was used to evaluate human myeloid (CFU-GM), erythroid (BFU-E) and mixed (CFU-GEMM) colony-forming progenitors (5). After 14 days of incubation at 37°C in a humidified 5% CO 2 atmosphere, colonies were scored by using an inverted microscope and applying standard criteria for their identification. After scoring, colonies were washed and analyzed for cytogenetics to establish their human or murine origin.
LTC-IC assays were performed, according to standard procedures (19, 20) , by seeding an aliquot of light density cells in dishes over an irradiated (1500 cGy) murine stromal cell line (M210-B4, kindly provided by C. Eaves), as previously described (6) . Briefly, cultures were incubated for 3 days under standard conditions and then switched to 33°C. At weekly intervals, half of the complete medium was removed and replaced by freshly prepared medium. After 5 weeks, cells were detached with trypsin and counted and aliquots were seeded in GF-supplemented semisolid medium (Methocult, Stem Cell Technologies) to determine the number of clonogenic precursors. After 14 days of culture at 37°C, colonies were scored and identified as described above.
Calculation of the total content of a cell population
The marrow content from both femurs of each mouse was assumed to contain approximately 12% of total BM cellularity (21); the total content of human cells was calculated as follows:
No. of human cells = (total femur cellularity × 100 / 12) × CD45 percentage / 100
The expansion rate was calculated as the ratio between the absolute number of a certain cell population detected in the mouse and the absolute number of the same population injected into the same animal.
In vivo protocols
Infusion of cADPR-primed cells
CB MNC (10 6 /ml) were incubated in a humidified 5% CO 2 atmosphere at 37°C in complete medium (IMDM containing 10% fetal bovine serum, plus L-glutamine, 100 U/ml; penicillin, 100 U/ml; and streptomycin, 100 µg/ml). cADPR or ADPR (each at 100 µM final concentration) was added once at the beginning of the incubation. After 24 h, cells were washed, and appropriate dilutions were resuspended in 200 µl PBS to be infused into the mice (4 animals for each experimental point, n = 6).
Secondary transplant
Marrow or spleen cells were removed from primary NOD/SCID recipients of cADPR-treated and ADPR-treated CB MNC at day +20 from transplant. Then, cells were counted and subjected to the immunophenotypic determinations described above (flow cytometry), and an equal cell number was infused into secondary recipients (4 animals for each experimental point, n = 4) to assess their engraftment capacity.
Co-infusion of CB MNC with cADPR-producing feeder cells
CB MNC (15 × 10 6 ) were co-infused with 10 6 irradiated (1500 cGy) NIH-3T3 fibroblasts transfected with either the sense (CD38 + ) or antisense (CD38 -) cDNA encoding for human CD38 (4 animals for each experimental point, n = 6). Stable transfectants, obtained as described in (7), were maintained under geneticin selection. One week prior to co-infusion, cells were transferred to a geneticin-free medium.
Assay of ADP-ribosyl cyclase activity and intracellular calcium measurement
Assays of ectocellular ADP-ribosyl cyclase activity were performed on CD38-transfected (both sense-and antisense-) 3T3 feeder cells as described (7), by using 0.2 mM NAD + as substrate.
Fluorimetric determinations of intracellular free calcium concentrations ([Ca
] i ) were performed on Fura2-AM-treated 3T3 fibroblasts, as described (7).
Statistical analyses
Statistical analyses were performed by using a Mann-Whitney Two-Sample (Non-Matched) Test (NCSS package; J.L. Hintze, Kaysville, UT; 1990).
RESULTS
In vitro treatment of human HP with cADPR increases engraftment into NOD/SCID mice
In vitro priming with cADPR (100 µM for 24 h) of human CB-derived MNC induces an expansion of both committed (CFC) (5) and uncommitted (LTC-IC) (6) hemopoietic progenitors (HP). As a consequence of this expansion, a slightly higher number of CFC and LTC-IC was infused in the mice receiving the cADPR-primed cells compared with controls, although the total cell number given to both animal groups was the same (median value 11.8 × 10 6 MNC; range [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] (range 0.3-9.8) for mice infused with cADPR-and ADPR-primed CB MNC, respectively. Mice were killed at day +20, +60, and +90 from transplant; human engraftment was assessed by immunofluorescence on total BM and spleen.
At day +20, mice infused with cADPR-primed cells (group 2) showed a slightly higher, not statistically significant, human cell (CD45 + ) engraftment in the spleen compared with controls (group 1) (Fig. 1 a) . In both animal groups, splenic engraftment of the mature (CD33 + ) and of the immature (CD34 + ) human cells was negligible from day +60 (Fig. 1c, e) .
In the BM, human engraftment (CD45 + ) was higher in the mice receiving the cADPR-primed cells (group 2) than in the controls (group 1), respectively, at day +20 (Fig. 1b) . At this time, both the mature (Fig. 1d ) and the immature (Fig. 1f ) compartments were larger in mice receiving the cADPR-treated cells. At days +60 and +90, human cells (CD45 + ) underwent a limited decrease in group 2 mice. At day +60, a marked decrease of CD33 + and CD34 + cells was observed in the BM of group 2 mice, followed by a partial recovery at day +90 (Fig. 1d, f) .
In parallel to the immunophenotypic analysis, cells recovered from transplanted mice were assayed in vitro for their colony-producing capacity, under conditions selective for human HP (22) . At all time points post-transplant, despite a high variability due to individual animal responses, an increased colony production was observed in the cADPR-treated group compared with controls, the corresponding differences being statistically significant only at day +90 (Table  1) . Thus, this functional assay highlights an improved proliferative potential of the clonogenic compartment, which was not detectable by simple phenotypic analysis.
Effect of cADPR priming on engraftment into secondary recipients
In an attempt to verify whether at day +20 an expansion of SCID-repopulating cells (SCID-RC) was underway, we killed mice from group 1 and group 2 (which received ADPR-and cADPRprimed cells, respectively) and MNC from their BM or spleen were infused into secondary recipients. The total cell input was 15 × 10 6 MNC. This schedule was suggested by the earlier finding that cADPR stimulates the in vitro proliferation and expansion of both committed (CFC) and early (LTC-IC) HP (5, 6). The fourfold expansion of LTC-IC, as induced both by exogenously added and by stroma-generated cADPR (6), led in fact to the expectation that this effect could be present already at day +20 and could progress toward an even longer lasting in vivo expansion. The choice of day +20 was suggested by the larger human engraftment at this time compared with the subsequent time points (Fig. 1) .
Secondary recipients were killed at day +60 to ascertain long-term engraftment. Group 2 mice showed a higher human engraftment (CD45 + cells) in the BM, both in the myeloid (CD33 + ) and in the more immature compartment (CD34 + ) compared with controls (P < 0.05) (Fig. 2) . Cells recovered from BM of both groups of mice were tested in vitro for human colony production.
Total CFC output for group 2 mice was significantly higher compared with controls, the median values were 11,600 versus 8,300 (range 5,300-30,780 and 1,790-13,500 respectively, P = 0.05).
To assess whether cADPR priming induced a selective homing of SCID-RC to BM or to spleen in the primary recipients, we performed a number of additional secondary transplants by using MNC recovered from either BM or spleen. The source of the cells proved irrelevant with respect to the effect of the cADPR priming, which was stimulatory in all cases (data not shown).
Increased hemopoietic engraftment following co-infusion of human CB-MNC with CD38 + murine feeder cell lines
Results obtained with the in vitro cADPR-primed HP suggested the need to evaluate whether comparable effects could be obtained by means of the in vivo generation of cADPR by CD38-transfected murine feeder cell lines. Since transfection, the ecto-ADP-ribosyl cyclase activity expressed by the CD38 + fibroblasts increased steadily: from 0.28 ± 0.03 nmoles cADPR/min/mg protein, as observed in the freshly established transfectants (7), up to 0.58 ± 0.04 nmoles cADPR/min/mg, as detected on the CD38 + feeder cells used in this study for the co-infusion experiments. The reason for this increase is likely to be the proliferative advantage induced by the autocrine production of cADPR (7, 8) , which maintains a selective pressure favoring the cells that express the highest levels of cyclase activity. The antisense transfected (CD38 -) feeder cells used as a control were devoid of any detectable cyclase activity. The cyclase activity expressed by the CD38 + feeders used in this study is approximately 25× higher than that measured on normal human BM stroma (0.023 nmoles cADPR/min/mg) (6).
The basal intracellular free calcium concentration ([Ca
2+
] i ) measured in CD38 + 3T3 cells (55 ± 5 nM) was higher than that recorded in the CD38 -controls (20 ± 2 nM), but similar to that reported for the freshly established transfectants (42 ± 3 nM), despite the twofold increase of cyclase activity developed since transfection. Recent results suggest that this apparent discrepancy (a twofold increase of cyclase activity with little impact on the [Ca 2+ ] i ) is due to the Ca 2+ -induced down-regulation of the connexin 43-mediated NAD + flux across cell membranes, which enables cADPR production by CD38. This [Ca 2+ ] i -mediated feedback mechanism limits consumption of the dinucleotide and overproduction of cADPR in CD38 + cells (23) .
We infused mice with 15 × 10 6 CB-MNC together with 10 6 sublethally irradiated CD38 -(group 1) or CD38 + (group 2) murine stromal cells. At day +20, no significant differences in the total human engraftment (CD45 + MNC) and in the mature (CD33 + ) and immature (CD34 + ) compartments emerged between the two groups. At day +60, however, group 2 animals showed a significantly (P < 0.04) higher CD34 + absolute number compared with the controls (group 1) (Table 2A) .
We next investigated the clonogenic capacity of BM cells from both groups of mice. The in vitro assay for colony growth showed an increased CFC production in group 2 animals compared with group 1 at both post-transplant time points, with the most significant difference at day +60 (Table 2B) . Thus, an increased clonogenic potential was observed in the human progenitors exposed to cADPR: either by in vitro incubation with the exogenously added molecule or by coinfusion with cADPR-producing stromal cells.
Effect of cADPR on CD34 + expansion
We calculated the expansion factor of CD34 + HP for all protocols used in this study (see Materials and Methods).
In vitro priming with cADPR induced a slightly higher, not statistically significant, expansion of CD34 + HP compared with controls at day +20 (36 vs. 29). At day +60, the expansion factor dropped to 7.6 (vs. 30 in the control), followed by a new increase at day + 90 (16.4 vs. 13.5) ( Table 3 ).
In the secondary transplant, the expansion factor for the cADPR-primed group was higher compared with control at both time points: day +20 (4.3 vs. 3.7, not statistically significant) and day +60 (16.5 vs. 2.3; P < 0.05).
The expansion factor in the co-infusion experiments was similar in both animal groups (coinfused with either CD38 + or CD38 -stroma) at day +20, but was significantly higher (P <0.05) at day +60 for the animals infused with the CD38 + stroma (57.0 vs. 16.7). Thus, exposure of human HP to cADPR, either by in vitro incubation with the cyclic nucleotide or by co-infusion with a cADPR-producing stroma, stimulates in vivo expansion of hemopoietic stem cells.
DISCUSSION
In the present study, the effect of cADPR on NOD/SCID mice repopulating cells (SCID-RC) was addressed using two different protocols: i) an in vitro priming schedule of CB-MNC with supplemented cADPR (100 µM for 24 h), similar to that followed for LTC-IC (6), and, ii) the coinfusion of CB-MNC with cADPR-producing murine feeder cell lines.
In vitro priming of CB-MNC with cADPR induced an expansion of both CFC and LTC-IC compared with controls, as detected with in vitro functional assays performed by using an aliquot of the graft taken immediately prior to infusion and seeded under the appropriate culture conditions (5, 6) . A comparable expansion was also observed in vivo early after transplant (day +20). Thus, the in vitro expansion of committed progenitors (5) was paralleled by a rapid in vivo overshoot of CD33 + and CD34 + human cells. On the contrary, the in vitro observed expansion of LTC-IC after cADPR priming was not predictive of a better engraftment capacity, which should have been detectable at day +60, conventionally considered the time point of maximal human engraftment into NOD/SCID mice (24) . At day +60, a marked decrease of both the mature (CD33 + ) and immature (CD34 + ) myeloid compartments was in fact observed in the cADPRtreated group, compared with controls (Fig. 1) . This biphasic repopulation pattern of the cADPRprimed cells might be due to an in vivo feed-back mechanism triggered by the initial (day +20) expansion of a mature myeloid population and resulting in the transient inhibition of differentiation of the more immature HP (25) . The sustained human colony production, which was conversely observed in vitro over the entire 90 days period (Table 1) , may support this possibility. However, experimental data favor the alternative view that the cADPR priming affects two different populations of HP: a more mature, cycling one, which differentiates rapidly and synchronously and produces high numbers of CD33 + and CD34 + cells shortly after engraftment (day +20); an immature, non-cycling population, which undergoes self-renewal divisions without differentiation and which is responsible for the long-term (day +90) recovery. This second hypothesis seems to be substantiated by the following facts: i) cADPR priming has been shown to affect both cycling, cytosine arabinoside-(Ara-C) sensitive and non-cycling, Ara-C resistant HP (5); ii) a higher engraftment capacity into secondary recipients was recorded for cells taken at day +20 from the cADPR-treated group (Fig. 2) , consistent with the expansion of very early HP being underway since the early phase of the primary transplant. It is interesting to note that the timing of the most significant increase of the CD34 + cell number, and of its expansion factor, in the secondary recipients from the cADPR-treated group compared with controls, which was recorded at day +60 (i.e., after 20 days primary transplant followed by 60 days secondary transplant), coincides with the timing of the long-term recovery of human engraftment in the primary transplant (day +90).
Also in the co-infusion experiments, day +60 was the time point at which the number of CD34 + cells showed the most significant (P<0.04) difference between group 1 and group 2 animals (Table 2A) . Accordingly, the high cADPR concentration (100 µM) used in the in vitro priming protocol seems to induce the synchronous advancement of a committed HP population along the differentiation pathway. However, cADPR production by the co-infused CD38 + feeder cells, though 25-fold higher than that of the endogenous stroma (on a per milligram protein basis), should account for an in vivo cADPR concentration several logs less than the one used for in vitro priming. In humans, the blood plasma levels of cADPR are close to 1 nm under normal conditions (26) . In the murine model used in this study, despite the simultaneous infusion of the human HP with the highly cADPR-producing CD38 + 3T3 cells, two facts contribute to the dilution of cADPR in the BM microenvironment: i) the low concentration of extracellular cADPR, which has been shown to be in the nanomolar range even in the medium conditioned by confluent CD38 + monolayers (6, 8) ; and, ii) the low seeding efficiency into the BM of the coinfused CD38 + feeder cells, which can be estimated at approximately 7% of the injected cells (27). However, HSC are likely to be exposed for several days to the continuous production of nanomolar cADPR concentrations in the BM microenvironment, until death of the irradiated feeder cells. Recently, we have identified concentrative mechanisms of cADPR influx into different mammalian cell types, which might result in the occurrence of functionally adequate cADPR levels in the HP (26) . Whatever the mechanism, as a result of this more physiological way of administration of the cyclic nucleotide, both in terms of concentration and of duration of exposure, cADPR induced a gradual expansion of HP, which improved long-term engraftment without inducing mid-term depletion. Indeed, among all experimental protocols used, the highest expansion factor of CD34 + cells was obtained with the co-infusion of CD38 + cells and HP, at day +60 (Table 3) . In any case, it should be stressed that the CD34 + expansion factor was higher in the treated animals (group 2) compared with controls (group 1) in all protocols used, both in the medium-and in the long-term post-transplant. This finding supports the conclusion that cADPR stimulates the expansion of totipotent HP, capable of self-renewal and repopulation of the irradiated host.
Our results thus extend the cADPR-sensitive HP population to include the HSC and suggest two possible applications of therapeutic use for cADPR as a hemopoiesis-stimulating factor. In vitro priming of an aliquot of marrow graft with micromolar cADPR concentrations, or with nanomolar concentrations of the analog 3-deaza-cADPR (5, 28) , could induce a rapid in vivo overshoot of maturing myeloid elements, due to a marked expansion of short-term repopulating cells. The protracted exposure to nanomolar cADPR concentrations, as produced by the coinfused CD38 + stroma, is expected to induce the expansion of long-term repopulating cells. In the clinical setting, a combination of the two protocols may reduce the aplasia period that immediately follows transplant and may improve long-term engraftment (29) . Irradiated, in vitro expanded, CD38-transduced autologous mesenchymal cells could be co-infused together with the HP to provide a transient and localized production of cADPR in the BM microenvironment. In vitro human colony production by bone marrow cells, recovered at different post-transplant time points, from mice injected with cADPR-primed or ADPR-primed (control) CB-MNC. Median values and range from six experiments are shown. BMT: bone marrow transplant. P calculated according to the Mann-Whitney two-sample test. P values are shown only for statistically significant differences between cADPR-primed and control, ADPR-treated CB-MNC injected into mice (day + 90). 
